Literature DB >> 27086006

A Practical Approach to Preventing Postoperative Recurrence in Crohn's Disease.

Jana G Hashash1, Miguel Regueiro2.   

Abstract

Postoperative Crohn's disease recurrence remains common, and preventing additional surgery remains a challenge. A critical step to postoperative management of Crohn's disease is being able to identify patients who should receive immediate postoperative therapy from the patients who can wait for recurrence prior to starting medications. All patients, regardless of their risk for recurrence, are advised to undergo a colonoscopy at 6 to 12 months after surgery to evaluate for endoscopic evidence of Crohn's disease. Further management of patients depends on symptoms and the presence or absence of endoscopic recurrence.

Entities:  

Keywords:  Anti-tumor necrosis factor; Immunomodulator; Postoperative Crohn’s disease; Prevention; Recurrence

Mesh:

Year:  2016        PMID: 27086006     DOI: 10.1007/s11894-016-0499-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  55 in total

1.  Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  C Florent; A Cortot; P Quandale; T Sahmound; R Modigliani; E Sarfaty; P Valleur; J L Dupas; M Daurat; J L Faucheron; E Lerebours; F Michot; J Belaiche; N Jacquet; J C Soulé; N Rothman; J P Gendre; M Malafosse
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-03       Impact factor: 2.566

2.  Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.

Authors:  Konstantinos Papamichael; Emmanuel Archavlis; Constantina Lariou; Gerassimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2012-03-15       Impact factor: 9.071

3.  Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission.

Authors:  Sunanda V Kane; Michael Flicker; Flora Katz-Nelson
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

Review 4.  Factors affecting recurrence after surgery for Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

5.  Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

Authors:  R Caprilli; M Cottone; F Tonelli; G Sturniolo; F Castiglione; V Annese; C Papi; A Viscido; C Cammà; G Corrao; G Latella
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

6.  The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies.

Authors:  George E Reese; Theodore Nanidis; Catherine Borysiewicz; Takayuki Yamamoto; Timothy Orchard; Paris P Tekkis
Journal:  Int J Colorectal Dis       Date:  2008-09-02       Impact factor: 2.571

7.  Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.

Authors:  Mariam Aguas; Guillermo Bastida; Elena Cerrillo; Belén Beltrán; Marisa Iborra; Cristina Sánchez-Montes; Fernando Muñoz; Jesús Barrio; Sabino Riestra; Pilar Nos
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

8.  Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.

Authors:  Alessandro Armuzzi; Carla Felice; Alfredo Papa; Manuela Marzo; Daniela Pugliese; Gianluca Andrisani; Francesco Federico; Italo De Vitis; Gian Lodovico Rapaccini; Luisa Guidi
Journal:  J Crohns Colitis       Date:  2013-06-27       Impact factor: 9.071

9.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

10.  Risk factors for early postoperative recurrence of Crohn's disease.

Authors:  E Lautenbach; J A Berlin; G R Lichtenstein
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  5 in total

1.  Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey.

Authors:  Vu Q Nguyen; Jessica L Mays; Marissa Lang; Yingxing Wu; Themistocles Dassopoulos; Miguel Regueiro; Alan Moss; Deborah D Proctor; Dario Sorrentino
Journal:  Dig Dis Sci       Date:  2017-11-17       Impact factor: 3.199

2.  CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry.

Authors:  In Young Choi; Sang Hyoung Park; Seong Ho Park; Chang Sik Yu; Yong Sik Yoon; Jong Lyul Lee; Byong Duk Ye; Ah Young Kim; Suk-Kyun Yang
Journal:  Korean J Radiol       Date:  2017-09-21       Impact factor: 3.500

Review 3.  Health Maintenance for Adult Patients with Inflammatory Bowel Disease.

Authors:  Jana G Hashash; Michael F Picco; Francis A Farraye
Journal:  Curr Treat Options Gastroenterol       Date:  2021-11-22

4.  Rate and risk factors of postoperative endoscopic recurrence of moderate- to high-risk Crohn's disease patients - A real-world experience from a Middle Eastern cohort.

Authors:  Nahla Azzam; Yazed AlRuthia; Abdulla Al Thaher; Majid Almadi; Othman Alharbi; Mansour Altuwaijri; Suliman Alshankiti; Mohammed Alanazi; Abdulelah Alanazi; Abdulrahman Aljebreen; Miguel Regueiro
Journal:  Saudi J Gastroenterol       Date:  2022 May-Jun       Impact factor: 3.214

5.  Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn's Disease.

Authors:  Jana G Hashash; Pamela L Beatty; Kristen Critelli; Douglas J Hartman; Matthew Regueiro; Hani Tamim; Miguel D Regueiro; David G Binion; Olivera J Finn
Journal:  J Clin Gastroenterol       Date:  2021-02-01       Impact factor: 3.174

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.